INNOVADERM CRO IS NOW INDERO.

Our Insights

FILTER BY:

Case Study

Systemic Sclerosis Case Study

Case Study

Urticaria Case Study

Case Study

Atopic Dermatitis (AD) Rescue Case Study

Case Study

A Success Story: Pre-IND and IND Support for an Alopecia Areata Investigational Product

Case Study

Plaque Psoriasis Case Study

Case Study

Nimbus Testimonial

Case Study

“Working with Indero for our alopecia areata trial has been a smooth and exceptional experience (…)” – An Inmagene Biopharmaceuticals Testimonial

Case Study

Success Story: Support for Vitiligo Pre-IND Submission and FDA Meeting Preparation

Case Study

Testimonial: “Thanks to Indero’s adaptive approach, we sailed through our trial with ease!”

Case Study

Indero, a Key Collaborator in Clinical and Study Development for Recently Published Phase 1 Atopic Dermatitis Study

Case Study

Generalized Pustular Psoriasis (GPP) Rescue Case Study

Case Study

Hidradenitis Suppurativa (HS) Case Study

Case Study

Palmoplantar Pustulosis (PPP) Case Study

Case Study

Notalgia Paresthetica (NP) Case Study

Case Study

Alopecia Areata (AA) Case Study

Case Study

Atopic Dermatitis (AD) Case Study

Case Study

Acne Case Study

FILTER BY:

News

Sustained Prominence: Indero Presents High‑Impact Clinical Research at AAD Late‑Breaking Sessions

News

Indero to Participate in the DIF Entrepreneur Bootcamp in Denver

News

Indero’s Breakfast Event at the AAD 2026: Navigating Placebo Response in Dermatology Trials

News

Indero Contributes to New British Journal of Dermatology Publication Exploring the Gut–Skin Connection in Chronic Hand Eczema

News

Join Us at AAD 2026 in Denver, Booth #3945!

News

Indero CRO and the World Scleroderma Foundation Announce Strategic Collaboration to Advance Early Therapeutic Intervention in Systemic Sclerosis

News

Join Indero at the AID’s Dermatology Summit in San Francisco!

News

Indero Named Best Employer by Mercer

News

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

FILTER BY:

Post

Your AAD 2026 Roadmap: 10 High-Impact Sessions to Prioritize in Denver

Post

Building Momentum in Clinical Trial Start‑Up

Post

Top Rheumatology Conferences to Attend

Post

The Strategic Power of Public Relations in Scientific and Technical Industries

Post

Rethinking CRA Oversight

Post

What Sites Look for in Sponsors: A Practical Checklist

Post

Aligning With Patient Advocates in Trials

Post

A Site-Centric Approach to Protocol Usability

Post

Enhancing Representation: Strategies for Patient Centricity in Inclusive Clinical Trials

FILTER BY:

White Paper

Centralized Monitoring: Exploring the Considerations and Challenges of Implementation

White Paper

Leveraging Technology in Phase I Clinical Trials

FILTER BY:

Webinar

Challenges of Managing Clinical Trials in Urticaria in 2025

Webinar

Updates on Chronic Spontaneous Urticaria

Webinar

Updates on Chronic Inducible Urticaria

Webinar

Exploring the Intersections: Dermatology and Rheumatology Insights

Webinar

Diving into the World of Adaptive Study Design – The Intersection of Statistics and Dermatology in Clinical Trials

Webinar

In-Person Breakfast Event at the AAD – Exploring the Innovation and Research on Alopecia Areata

Webinar

“Clinical Development Strategy that Patients Need and Investors Want” by Dr. Jasmina Jankicevic

Webinar

On the Edge of Dermatology Early Phase Trials

Webinar

Dr. Robert Bissonnette and Dr. Kim Papp on Shaping the Future of Clinical Research

FILTER BY:

One-Pager

Rheumatology Trial Readiness Checklist

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.